Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 1.097
Filter
1.
Brasília; s.n; 14 maio 2020.
Non-conventional in Portuguese | LILACS (Americas), ColecionaSUS, PIE | ID: biblio-1097392

ABSTRACT

Essa é uma produção do Departamento de Ciência e Tecnologia (Decit) da Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (SCTIE) do Ministério da Saúde (Decit/SCTIE/MS), que tem como missão promover a ciência e tecnologia e o uso de evidências científicas para a tomada de decisão do SUS, tendo como principal atribuição o incentivo ao desenvolvimento de pesquisas em saúde no Brasil, de modo a direcionar os investimentos realizados em pesquisa pelo Governo Federal às necessidades de saúde pública. Informar sobre as principais evidências científicas descritas na literatura internacional sobre tratamento farmacológico para a COVID-19. Além de resumir cada estudo identificado, o informe apresenta também uma avaliação da qualidade metodológica e a quantidade de artigos publicados, de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, entre outros). Foram encontrados 15 artigos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Disease Progression , Betacoronavirus/drug effects , Primaquine/therapeutic use , Ivermectin/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , BCG Vaccine/administration & dosage , Extracorporeal Membrane Oxygenation/instrumentation , Chloroquine/therapeutic use , Azithromycin/therapeutic use , Ritonavir/therapeutic use , Losartan/therapeutic use , Antiretroviral Therapy, Highly Active/instrumentation , Drug Combinations , Oseltamivir/therapeutic use , Lopinavir/therapeutic use , Darunavir/therapeutic use , Telmisartan/therapeutic use , Hydroxychloroquine/therapeutic use , Anticoagulants/therapeutic use
2.
Rev. ADM ; 77(2): 100-107, mar.-abr. 2020. ilus, tab
Article in Spanish | LILACS (Americas) | ID: biblio-1102211

ABSTRACT

El sarcoma de Kaposi (SK) es una neoplasia vascular maligna poco frecuente, asociada al virus herpes humano tipo 8. Existen cuatro formas clínicas: clásico, endémico, asociado con inmunosupresión iatrogénica y asociado al VIH/SIDA. Este artículo presenta una revisión de la literatura sobre la epidemiología, la patogénesis, las manifestaciones clínicas y el tratamiento del sarcoma de Kaposi asociado al VIH/ SIDA (SK-VIH/SIDA) a propósito de un caso clínico manejado en la Clínica Académica de Atención Dental. La baja en la incidencia de esta neoplasia da lugar al desconocimiento de sus manifestaciones clínicas. En adición, los pacientes seropositivos suelen no mencionar su padecimiento en la anamnesis, lo cual representa un riesgo tanto para el paciente en su diagnóstico y manejo odontológico como para el odontólogo y el personal clínico con riesgo de contagio (AU)


Kaposi sarcoma (KS) is an uncommon malignant vascular neoplasm, associated with human herpes virus type 8. There are four clinical presentations: classic, endemic, associated with iatrogenic immunosuppression and associated with AIDS. This article presents a review of the literature on epidemiology, pathogenesis, clinical manifestations, treatment and HIV/AIDS-associated Kaposi sarcoma (SK-HIV/AIDS) regarding a clinical case managed at the Academic Center of Dental Care. The decrease in the incidence of this neoplasm, leads to ignorance of its clinical manifestations. In addition, seropositive patients usually don't mention their condition in the anamnesis, which represents a risk for the patients on their diagnosis and the case management as well as for the dentist and the clinical personnel from risk of infection (AU)


Subject(s)
Humans , Male , Adult , Oral Manifestations , Sarcoma, Kaposi , HIV Infections/complications , Dental Care for Chronically Ill , Sarcoma, Kaposi/diagnostic imaging , Communicable Disease Control , Infection Control, Dental , Antiretroviral Therapy, Highly Active , Mexico
3.
Rev. bras. ciênc. saúde ; 24(1): 57-62, 2020. ilus
Article in Portuguese | LILACS (Americas) | ID: biblio-1087474

ABSTRACT

Objetivo: Avaliar a influência da terapia na morfologia da epiderme de pacientes com Síndrome da Imunodeficiência Adquirida - AIDS. Metodologia: Estudo transversal desenvolvido na Universidade Federal do Triângulo Mineiro, Brasil. Foram selecionados pacientes com AIDS de ambos os sexos, que foram agrupados de acordo com o tratamento com Terapia antir-retroviral de alta eficiência: pacientes em uso de HAART (n = 14) e pacientes sem uso de HAART (n = 14). Outras informações foram coletadas do prontuário clínico. Resultados: A idade média dos pacientes em tratamento foi de 49,07 ± 7,89 anos e dos pacientes sem TARV foi de 55,11 ± 10,17 anos. A maioria dos pacientes na terapia utilizada pertencia ao sexo feminino, 9 (64,28%). Estes apresentaram espessamento epidérmico (150,04 x 86,09µm), número de camadas celulares (8,0 x 5,5 camadas) e densidade de células de Langerhans superiores àquelas que não utilizaram a terapia, com diferença significativa. Conclusão: Nossos achados sugerem que o HAART propor-ciona a recuperação dos constituintes da epiderme alterados pela doença, melhorando sua função como barreira chave na proteção do corpo contra microorganismos ambientais. (AU)


Objective: To evaluate the influence of therapy in the morphology of the epidermis of patients with Acquired Immunodeficiency Syndrome. Methodology: Cross-sectional study developed at the Triangulo Mineiro Federal University, Brazil. This study has been approved by Triângulo Mineiro Federal University Research Ethics Committee on protocol number 1780/2010. Patients with AIDS, of both genders were selected and arranged according to treatment with Highly Active Antiretroviral Therapy: patients in use of HAART (n = 14), and patients without use of HAART (n = 14). Other information was collected from the clinical record. Results: The mean age of the patients undergoing therapy was 49.07±7.89 years, and of the patients without HAART was 55.11±10.17 years. The majority of the patients using the therapy, belonged to the female gender, 9 (64.28%). These showed epidermal thickness (150.04 x 86.09µm), number of cell layers (8.0 x 5.5 layers) and density of Langerhans cells higher than those who did not use the therapy, with a significant difference. Conclusion: Our findings suggest that the HAART provides recovery of epidermis constituents altered by the disease, improving its function as a key barrier in protecting the body against environmental microorganisms. (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Acquired Immunodeficiency Syndrome , Antiretroviral Therapy, Highly Active , Epidermal Cells , Aging
4.
Rev. Pesqui. (Univ. Fed. Estado Rio J., Online) ; 11(5): 1260-1265, out.-dez. 2019.
Article in English, Portuguese | LILACS (Americas), BDENF | ID: biblio-1022614

ABSTRACT

Objective: The study's purpose has been to scrutinize the changes in women's daily life, as well as to investigate how they stand after the diagnosis of HIV/AIDS and the introduction of Antiretroviral Therapy (ART). Methods: It is a descriptive and prospective study with a qualitative approach. Semi-structured interviews were performed with twenty-two HIV positive women, who were enrolled in the immunology ambulatory of a university hospital located in the Rio de Janeiro city. This research was approved by the Research Ethics Committee (CAAE: 45955315.0.0000.5285). Results: Most women dealt positively with the changes in their daily lives after discovering the disease, looking for a way of life with quality, although they still show some difficulties in that regard. Concerning the ART, there was struggle in its beginning; however, as the time went by the adaptations occurred mainly with the family support. Conclusion: It is essential to provide better support towards women during both HIV diagnosis and treatment, so that they can improve their coping strategies


Objetivo: Investigar as mudanças no cotidiano e analisar o enfrentamento de mulheres após o diagnóstico do HIV/AIDS e a introdução da Terapia Antirretroviral (TARV). Método: Estudo descritivo e prospectivo de natureza qualitativa. Realizadas entrevistas semiestruturadas com vinte e duas mulheres HIV positivas, matriculadas no ambulatório de imunologia de um hospital universitário do Rio de Janeiro. Aprovado pelo Comitê de Ética CAAE: 45955315.0.0000.5285. Resultados: A maioria das mulheres enfrentou positivamente as mudanças no seu cotidiano após a descoberta da doença, buscando viver com qualidade, embora ainda apresentem dificuldades na retomada de suas vidas. Com relação à TARV houve dificuldade em seu início, no entanto com o passar do tempo ocorreram adaptações principalmente com o apoio da família. Conclusão: É fundamental que haja um maior apoio as mulheres durante o diagnóstico e tratamento do HIV, para que possam elaborar melhor suas estratégias de enfrentamento


Objetivo: Investigar los cambios en la rutina y hacer un análisis del enfrentamiento de mujeres tras el diagnóstico del VIH/sida y la introducción de la Terapia Antirretroviral (TARV). Método: Estudio descriptivo y prospectivo de naturaleza cualitativa. Se realizaron entrevistas semiestructuradas con veintidós mujeres VIH positivas, matriculadas en el ambulatorio inmunológico de un hospital universitario de Río de Janeiro. Aprobado por el Comité de Ética CAAE: 45955315.0.0000.5285. Resultados: La mayoría de las mujeres enfrentó positivamente los cambios en su cotidiano después del descubrimiento de la enfermedad, buscando vivir con calidad, aunque todavía presentan dificultades en la reanudación de sus vidas. En cuanto a la TARV hubo dificultad en su inicio, sin embargo con el paso del tiempo ocurrieron adaptaciones principalmente con el apoyo de la familia. Conclusión: El apoyo a las mujeres durante el diagnóstico y tratamiento del VIH es fundamental, para que puedan elaborar sus estrategias de enfrentamiento


Subject(s)
Humans , Female , Adult , Middle Aged , Social Support , Acquired Immunodeficiency Syndrome/psychology , HIV , Antiretroviral Therapy, Highly Active/psychology , Family/psychology
6.
Prensa méd. argent ; 105(3): 99-105, may 2019. tab
Article in Spanish | LILACS (Americas), BINACIS | ID: biblio-1025198

ABSTRACT

Introducción: El tratamiento antirretroviral de alta eficacia (TARGA) ha desplazado a las infecciones oportunistas como principal causa de hospitalización en infectados por el HIV. Sin embargo, algunos autores hallaron que las causas de internación por HIV en Buenos Aires no cambiaron a pesar del acceso universal al TARGA desde 1996. Pacientes y Métodos. Para confirmar estos resultados revisamos todos los ingresos hospitalarios ocurridos durante tres años en un hospital general de la ciudad de Buenos Aires. Resultados: 57 pacientes (34 hombres) tuvieron 79 hospitalizaciones: 43 ingresaron sólo una vez y los 14 restantes tuvieron dos o más ingresos hasta totalizar 36 internaciones. La edad fue de 44.46 ± 11.55 años (promedio ± desvío estándard), 43 pacientes (75.45%) se sabían HIV + y 28 de ellos (65.12%) recibían TARGA al ingreso, 31 hospitalizaciones (39.24%) fueron causadas por enfermedades marcadoras de SIDA; 35 (44.30%) por infecciones no marcadoras de SIDA (INMS) y 13 (13.46%) por enfermedades no infecciosas. Tuberculosis fue el diagnóstico más frecuente (11 casos, 13.92%), seguida por meningitis a Cryptococcus neoformans en 9 (11.39%) y toxoplasmosis cerebral en 6 (7.59%). Entre las INMS, la neumonía fue la principal causa de hospitalización (13 pacientes, 16.46%). Discusión: Estos resultados confirman resultados previos comunicando que las causas de hospitalización en infectados por el HIV no cambiaron en respuesta al TARGA en Buenos Aires, lo que puede estar reflejando problemas de detección o adherencia, o puede estar relacionado con resistencia viral, razones sociales o cualquier combinación de estos factores (AU)


Introduction. High Active Antiretroviral Treatment (HAART) displaced opportunistic infections as the main cause of hospitalization in HIV infected patients. However, some authors found that causes for hospitalization in HiV infected patients did not changed at Buenos Aires although this country offers universal access to HAART since 1996. Patients and Methods. We analyzed all the HIV related admissions recorded during three years at a general hospital. Results. 57 patients (34 men) were hospitalized 79 times. 43 out of them were hospitalized only one time. The reaining 14 were hospitalized 36 times. Age was 44.46 ± 11.55 years (mean ± standard deviation). 43 patients (75.45%) had a previous diagnosis of HIV infection. 28 of them (65.12%) received HAART. 31 hospitalizations (39.24%) were caused by AIDS defining events. 35 (44.30%) related to non-AIDS-defining infections diseases (NADID), and 13 (13.46%) to non-infections diseases. Tuberculosis was the prevalent illness (11 cases, 13.92%), followed by cryptoccal meningitis in 9 (11.39%) and cerebral toxoplasmosis in 6 (7.59%). Among NADID, pneumonia was the main cause of admission (13 patientes, 16,46%). Discussion: These results confirm previous reports showing that causes of HIV related hospitalization remain unchanged in spite of HAART at Buenos Aires, which may be reflecting problems of detection and adherence, or may be related to local viral resistance, social reasons, or any combination of these factors (AU)


Subject(s)
Humans , Adult , Middle Aged , Communicable Diseases/diagnosis , Statistical Analysis , Retrospective Studies , HIV/immunology , Antiretroviral Therapy, Highly Active/statistics & numerical data , Drug Resistance, Viral/immunology , Noncommunicable Diseases , Inpatients/statistics & numerical data
7.
Prensa méd. argent ; 105(1): 16-23, mar 2019. graf, fig
Article in Spanish | LILACS (Americas), BINACIS | ID: biblio-1026319

ABSTRACT

En el presente trabajo se seleccionaron pacientes adultos HIV en tratamiento antirretroviral que contenían efavirenz de más de tres años de duración que hubieron tenido efectos adversos del sistema nervioso central iniciales, comprobando la desaparición completa de los mismos en el 94% de los pacientes evaluados al cabo de 36 meses de tratamiento. Se empleó como método el análisis observacional retrospectivo, utilizando una encuesta de valoración de frecuencia temporal de efectos adversos del sistema nervioso central. Se tuvieron en cuenta los siguientes: mareos: depresión; trastornos del sueño; pesadillas e ideación suicida. De los efectos adversos del sistema nervioso central investigados, los más frecuente fue pesadillas 100% y mareos 81%. Esta frecuencia decreciente hasta su desaparición, fortalece la hipótesis del "fenómeno de tolerancia" similar al observado con ciertas indolaminas, debido a que efavirenz presenta una similitud estructural con estas e interacciona con algunos receptores de la superfamilia de receptores de 5 hidroxitriptamina (5HT). Además las diferencias interindividuales de efectos adversos del SNC podrían estar dadas por las diferencias alélicas en citocromo p 450 que determinan niveles plasmáticos de metabólitos hidroxilados neurotóxicos


In the present study, adult HIV patients were selected on antiretroviral treatment that contained efavirenz for more than three years that had adverse effects on the initial central nervous system, proving their complete disappearance in 94% of the patients evaluated after 36 months of treatment. A retrospective observational analysis was used as a method, using a survey of temporal frequency assessment of adverse effects of the central nervous system. The following were taken into account: dizziness; anxiety; depression; sleep disorders; nightmares and suicidal ideation. Of the adverse effects of the central nervous system investigated, the most frequent was nightmares 100% and dizziness 81%. This decreasing frequency until its disappearance, strengthens the hypothesis of the "tolerance phenomenon" similar to that observed with certain indolamines, because efavirenz has a structural similarity with these and interacts with some receptors of the superfamily of 5-hydroxytryptamine (5HT) receptors. In addition, the interindividual differences of CNS adverse effects could be due to allelic differences in cytochrome p 450 that determine plasma levels of neurotoxic hydroxylated metabolites.


Subject(s)
Humans , Adult , Middle Aged , Central Nervous System/drug effects , Retrospective Studies , HIV/drug effects , Antiretroviral Therapy, Highly Active/adverse effects , Drug-Related Side Effects and Adverse Reactions/therapy , Time-to-Treatment , Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/adverse effects
9.
J. pediatr. (Rio J.) ; 95(1): 7-17, Jan.-Feb. 2019. tab, graf
Article in English | LILACS (Americas) | ID: biblio-984644

ABSTRACT

Abstract Objectives: Human immunodeficiency virus infection can result in the early impairment of anthropometric indicators in children and adolescents. However, combined antiretroviral therapy has improved, in addition to the immune response and viral infection, the weight and height development in infected individuals. Therefore, the objective was to evaluate the effect of combined antiretroviral on the growth development of human immunodeficiency virus infected children and adolescents. Source of data: A systematic review was performed. In the study, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) strategy was used as the eligibility criterion. The MEDLINE-PubMed and LILACS databases were searched using these descriptors: HIV, children, growth, antiretroviral therapy. The objective was defined by the population, intervention, comparison/control, and outcome (PICO) technique. Inclusion and exclusion criteria were applied for study selection. Synthesis of data: Of the 549 studies indexed in MEDLINE-PubMed and LILACS, 73 were read in full, and 44 were included in the review (33 showed a positive impact of combined antiretroviral therapy on weight/height development, ten on weight gain, and one on height gain in children and adolescents infected with human immunodeficiency virus). However, the increase in growth was not enough to normalize the height of infected children when compared to children of the same age and gender without human immunodeficiency virus infection. Conclusions: Combined antiretroviral therapy, which is known to play a role in the improvement of viral and immunological markers, may influence in the weight and height development in children infected with human immunodeficiency virus. The earlier the infection diagnosis and, concomitantly, of malnutrition and the start of combined antiretroviral therapy, the lower the growth impairment when compared to healthy children.


Resumo Objetivos: A infecção pelo vírus da imunodeficiência humana pode comprometer, precocemente, os indicadores antropométricos de crianças e adolescentes. No entanto, a terapia antirretroviral combinada tem melhorado, além da resposta imunológica e da infecção viral, o ganho pôndero-estatural dos infectados. Dessa forma, nosso objetivo foi avaliar o efeito da terapia antirretroviral combinada no crescimento, de crianças e adolescentes, infectadas pelo vírus da imunodeficiência humana. Fonte dos dados: Foi realizada uma revisão sistemática. No estudo, adotou-se como critério de elegibilidade dos artigos, a estratégia PRISMA (preferred reporting items for systematic reviews and meta-analyses). Foram consultadas as bases de dados MEDLINE-PubMed e LILACS pelos descritores: HIV (vírus da imunodeficiência humana), children, growth, antiretroviral therapy. O objetivo foi definido pela estratégia PICO (population, intervention, comparison/control, outcome). Critérios de inclusão e exclusão foram aplicados na seleção dos estudos. Síntese dos dados: Dos 549 estudos indexados no MEDLINE-PubMed e LILACS, 73 foram lidos na íntegra - 44 incluídos na revisão (33 demonstraram impacto positivo da terapia antirretroviral combinada no ganho pôndero-estatural, dez no ganho de peso e um no de estatura, em crianças e adolescentes, infectados com vírus da imunodeficiência humana). No entanto, o incremento no crescimento não foi o suficiente para normalizar a estatura de crianças infectadas, quando comparado com crianças da mesma idade e sexo, sem infecção pelo vírus da imunodeficiência humana. Conclusões: A terapia antirretroviral combinada que, conhecidamente, atua na melhora de marcadores virais e imunológicos, pode influenciar no ganho pôndero-estatural de crianças infectadas com vírus da imunodeficiência humana. Quanto mais precoce o diagnóstico da infecção e, concomitante, desnutrição e início da terapia antirretroviral combinada, menores serão os prejuízos no crescimento, quando comparado às crianças saudáveis.


Subject(s)
Humans , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Young Adult , Body Height/drug effects , Body Weight/drug effects , Child Development/drug effects , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Growth/drug effects , HIV Infections/drug therapy
10.
Article in English | WPRIM (Western Pacific) | ID: wprim-739011

ABSTRACT

BACKGROUND: Genetic variants and haplotypes of the interleukin-10 (IL10) gene have been shown to affect clinical outcomes, including the incidence of opportunistic infections (OIs), in HIV-infected patients. This study investigated the effect of IL10 gene variants on susceptibility to OIs in HIV-infected Korean patients in the era of highly active antiretroviral therapy (HAART). METHODS: Eighty-five HIV-infected patients receiving HAART were enrolled in the study. OIs were diagnosed based on the published criteria of the Korean Society for AIDS. Three promoter SNPs and four haplotype-tagging SNPs (htSNPs) of IL10 were selected and genotyped. The haplotypes were reconstructed according to the genotyping data and linkage disequilibrium (LD) status of these SNPs. RESULTS: During the study, 38 OIs developed in 23 of the 85 patients (27.1%), at a rate of 1.7 episodes/patient. Carrying the minor alleles at the rs1518111, rs3024490, and rs1800871 SNPs had a protective effect against OIs (adjusted P=0.035). Among the seven assessed variants, only three possible haplotypes were observed. The second most common haplotype, which was composed of the rs1518111 minor allele and the rs3021094 major allele showed a protective effect against OIs (P=0.0153). CONCLUSION: This study demonstrated that some IL10 genetic variants and haplotypes are associated with protective effects against OIs in the era of HAART. These data suggest the potential of two htSNPs, rs1518111 and rs3021094, as markers revealing the genetic association of IL10 in Koreans. This is the first report on the association of IL10 with OIs in HIV-infected Korean patients in the era of HAART.


Subject(s)
Alleles , Antiretroviral Therapy, Highly Active , Haplotypes , HIV , Humans , Incidence , Interleukin-10 , Korea , Linkage Disequilibrium , Opportunistic Infections , Polymorphism, Single Nucleotide
11.
J. pediatr. (Rio J.) ; 95(supl.1): S95-S101, 2019.
Article in English | LILACS (Americas) | ID: biblio-1002484

ABSTRACT

Abstract Objective: Weight and height growth impairment is one of the most frequent manifestations in HIV-infected children and may be the first sign of disease, being considered a marker of disease progression and an independent risk factor for death. The aim of this review is to evaluate the influence of antiretroviral therapy on the growth pattern of children and adolescents living with HIV/AIDS. Source of data: A non-systematic review was carried out in the PubMed database, with the terms "HIV", "Weight and height growth", "ART" and "children". The most relevant publications were selected. Data Synthesis: Antiretroviral therapy has significantly reduced morbidity and mortality in HIV-infected children and is clearly associated with recovery of weight and height-for-age Z-scores, especially when started early, in the asymptomatic child still without weight-height impairment. Therapeutic strategies involving the GH/IGF-1 axis, especially for children with growth impairment, are still being studied. Conclusions: HIV-infected children show early weight-height impairment; antiretroviral therapy improves the anthropometric profile of these children.


Resumo Objetivo: O acometimento do desenvolvimento pondero-estatural é uma das manifestações mais frequentes nas crianças infectadas pelo HIV e pode ser o primeiro sinal de doença, é considerado um marcador de progressão para doença e um fator de risco independente para morte. O objetivo desta revisão é avaliar a influência da terapia antirretroviral no padrão de crescimento em crianças e adolescentes vivendo com HIV/Aids. Fonte dos dados: Foi feita uma revisão não sistemática na base de dados PubMed, com os termos "HIV", "desenvolvimento pondero estatural", "TARV" e "crianças". Foram selecionadas as publicações mais relevantes. Síntese dos dados: A terapia antirretroviral reduziu substancialmente a morbimortalidade em crianças infectadas pelo HIV e está claramente associada à recuperação do escore-z de peso e de estatura para idade, principalmente quando iniciada precocemente, na criança assintomática e ainda sem comprometimento pondero-estatural. Estratégias terapêuticas que envolvem o eixo GH/IGF-1, principalmente para crianças com comprometimento do crescimento, ainda estão em estudo. Conclusões: As crianças infectadas pelo HIV apresentam comprometimento pondero-estatural precoce e a terapia antirretroviral melhora o perfil antropométrico dessas crianças.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Body Height/drug effects , HIV Infections/drug therapy , Child Development/physiology , Anti-HIV Agents/therapeutic use , Growth and Development/drug effects , Growth Disorders/physiopathology , HIV Infections/physiopathology , Child Development/drug effects , Disease Progression , Anti-HIV Agents/adverse effects , Antiretroviral Therapy, Highly Active , Growth and Development/physiology , Growth Disorders/chemically induced
12.
Cad. Saúde Pública (Online) ; 35(5): e00184218, 2019. tab, graf
Article in English | LILACS (Americas) | ID: biblio-1001674

ABSTRACT

Abstract: This study sought to develop and evaluate a new patient-reported outcome measure to assess perceived barriers to antiretroviral therapy (ART) adherence. The Perceived Barriers to Antiretroviral Therapy Adherence (PEDIA) scale was developed based on individual interviews with patients. After pilot testing and assessing the evidence based on content analysis, the scale's revisions resulted in a 40-item version. The PEDIA was applied to 415 HIV-infected adults receiving ART for a maximum of 180 days, recruited from three healthcare facilities of reference in the city of Belo Horizonte, Minas Gerais State, Brazil. The analyses included exploratory factor analysis, internal consistency, item response theory, temporal stability, and predictive test-criterion relationship. The scale's final version contains 18 items distributed in three dimensions, as follows: cognitive and routine problems (4 items); medication and health concerns (6 items); and patient's fears and feelings (8 items). The results of McDonald's omega and temporal stability demonstrate that the PEDIA is internally consistent and yields stable scores over time. The assessment of the information's functions suggested that the three dimensions were informative for assessing a broad range of latent traits. Evidence concerning the test-criterion relationship confirmed that the PEDIA was able to predict non-adherence three months later. Our findings suggest that the PEDIA is a psychometrically adequate tool for evaluating perceived barriers in adult patients initiating ART. It could be used in both research and clinical practice for the early detection of patients at risk of non-adherence and for the identification of potentially modifiable barriers.


Resumo: Este estudo teve por objetivo o desenvolvimento e avaliação de uma nova medida de desfecho relatada pelo paciente para avaliar barreiras percebidas à adesão à terapia antirretroviral (TARV). A escala Percepção de Dificuldades com o Tratamento Antirretroviral (PEDIA) foi desenvolvida com base em entrevistas com pacientes. Após teste piloto e avaliação de evidências com base no conteúdo do teste, revisões da escala resultaram em uma versão com 40 itens. A PEDIA foi aplicada em 415 adultos soropositivos para HIV que receberam TARV por um máximo de 180 dias, recrutados de três unidades de saúde de referência na cidade de Belo Horizonte, Minas Gerais, Brasil. As análises incluíram análise fatorial exploratória, consistência interna, teoria da resposta ao item, estabilidade temporal, e relação preditiva teste-critério. A versão final da escala contém 18 itens distribuídos em três dimensões, no caso: problemas cognitivos e de rotina (4 itens); preocupações com medicamentos e saúde (6 itens); e medos e sentimentos do paciente (8 itens). Resultados do ômega de McDonald e estabilidade temporal demonstram que a PEDIA é internamente consistente e produz escores estáveis ao longo do tempo. As funções de informação do teste sugerem que as três dimensões foram informativas na avaliação de uma ampla gama do traço latente. Evidências relacionadas à relação teste-critério confirmaram que a PEDIA foi capaz de prever não-adesão três meses depois. Nossos resultados sugerem que a PEDIA é uma ferramenta robusta do ponto de vista psicométrico para a avaliação das barreiras percebidas por pacientes adultos que iniciam TARV. Ela pode ser usada em contextos clínicos e de pesquisa para a detecção precoce de pacientes em risco de não-adesão e para a identificação de barreiras potencialmente modificáveis.


Resumen: Este estudio se propone desarrollar y evaluar una nueva medida de resultados informados por los pacientes para evaluar los obstáculos percibidos en la adherencia a la terapia antirretroviral (ARV). Las barreras percibidas para la adherencia a la terapia antirretroviral según la escala Percepción de Dificuldades con el Tratamiento Antirretroviral (PEDIA) se desarrollaron basándose en entrevistas a pacientes individuales. Tras unas pruebas piloto, y evaluando evidencias basadas en el contenido de las pruebas, las revisiones de la escala resultaron en una versión de 40 ítems. PEDIA se administró a 415 adultos infectados de VIH que recibían ARV durante un máximo de 180 días, captados en tres centros de salud de referencia en la ciudad de Belo Horizonte, Minas Gerais, Brasil. Los análisis incluyeron el análisis exploratorio factorial, la consistencia interna, la teoría de respuesta al ítem, estabilidad temporal, y validez de criterio en las pruebas predictivas. La versión final de la escala final cuenta con 18 ítems distribuidos en las siguientes tres dimensiones: problemas cognitivos y rutinarios (4 ítems); medicación y problemas de salud (6 ítems); además de miedos y sentimientos del paciente (8 ítems). Los resultados del omega McDonald y la estabilidad temporal demuestran que PEDIA es internamente consistente y obtiene puntuaciones estables en marcadores con el paso de los años. Las pruebas de información sugirieron que las tres dimensiones fueron informativas, evaluando un amplio abanico de características latentes. Las evidencias respecto a la relación entre las pruebas y los criterios confirmaron que PEDIA era capaz de predecir la no-adherencia tres meses después. Nuestros resultados sugieren que PEDIA es una herramienta psicométrica para evaluar los obstáculos percibidos en pacientes adultos que comienzan una ARV. Se puede utilizar tanto en el entorno de investigación, como en el de la práctica clínica para una detección temprana de pacientes con riesgo de no adherencia y la identificación de obstáculos potencialmente modificables.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , HIV Infections/drug therapy , Antiretroviral Therapy, Highly Active , Anti-Retroviral Agents/therapeutic use , Medication Adherence/statistics & numerical data , Patient Reported Outcome Measures , Psychometrics , Brazil , Communication Barriers , Self Report
13.
Annals of Dermatology ; : 640-644, 2019.
Article in English | WPRIM (Western Pacific) | ID: wprim-762393

ABSTRACT

BACKGROUND: In Korea, new human immunodeficiency virus (HIV) patients continue to be diagnosed. Due to the development of highly active anti-retroviral therapy (HAART) and lengthening of survival period of infected person, the aspect of skin diseases of HIV-infected patients is also changing. OBJECTIVE: To determine skin diseases of HIV-infected patients according to immune status and the relationship between folliculitis and HAART drug. METHODS: Subjects were HIV-infected patients who were treated in the department of dermatology from September 1, 2008 to August 31, 2018. Medical records of 376 subjects were retrospectively analyzed. RESULTS: Of 376 patients were studied, tinea infection, folliculitis, and seborrheic dermatitis were the most common regardless of their CD4 T cell counts or treatment group (initial treatment or retreatment). Seborrheic dermatitis, irritant contact dermatitis, and pruritic papular eruption were significantly more common in patients with CD4+T cells less than 200×106 cells/L while warts were significantly more frequent in patients with CD4+T cells greater than 200×106 cells/L. Most HAART agents were found to be helpful in reducing the incidence of folliculitis. CONCLUSION: There were many skin diseases in HIV patients, different from previous studies. In our study, the top three diagnoses were tinea infection, folliculitis, and seborrheic dermatitis. HAART medication was helpful in reducing folliculitis. These changes will require different treatments for skin diseases in HIV patients.


Subject(s)
Acquired Immunodeficiency Syndrome , Antiretroviral Therapy, Highly Active , Cell Count , Dermatitis, Contact , Dermatitis, Seborrheic , Dermatology , Diagnosis , Folliculitis , HIV , Humans , Incidence , Korea , Medical Records , Retrospective Studies , Skin Diseases , Skin , Tinea , Warts
14.
Biomédica (Bogotá) ; 38(4): 527-533, oct.-dic. 2018. tab, graf
Article in English | LILACS (Americas) | ID: biblio-983963

ABSTRACT

Introduction: Since the beginning of the epidemic, human immunodeficiency virus (HIV) has taken more than 36 million lives. Objective: To determine the antiretroviral drug prescription patterns in a population of individuals with HIV infection in Colombia. Materials and methods: Cross-sectional study analyzing the profiles of patients treated with antiretroviral drugs between April 1st and September 30th, 2015. The sociodemographic, pharmacological, and comorbidity variables were identified. Individuals with a positive diagnosis of HIV of all ages and both genders were included. Results: We found 641 patients with a mean age of 39.0±17 years who were predominantly male (60.2%). The most used medications were lamivudine-zidovudine (51.6%), lopinavir-ritonavir (36%) and efavirenz (24.5%). The combination of lamivudine-zidovudine plus lopinavir-ritonavir was the most prescribed regimen (29.5%), but a total of 80 different regimens was identified. Being an adult between the ages of 45-64 years (OR=2.25; 95%CI 1.367-3.713) was associated with a greater probability of receiving 4 or more antiretrovirals. A total of 267 (41.6%) patients used at least one comedication (range: 1-18 drugs), especially anti-ulcer (57.3%), lipid-lowering (28.8%) and anti-hypertensive (28.5%) drugs. Conclusions: Patients undergoing antiretroviral treatment are receiving medications with elevated intrinsic values at the recommended doses and present comorbidities associated with chronic agerelated conditions. However, these patients receive a great variety of regimens that are not included in the clinical practice guidelines.


Introducción. La infección por HIV es una pandemia que actualmente se controla con el tratamiento farmacológico, el cual, además, prolonga la expectativa de vida del paciente. Objetivo. Determinar los patrones de prescripción de fármacos antirretrovirales en una población de personas afiliadas al régimen contributivo del Sistema General de Seguridad Social en Salud de Colombia, durante el 2015. Materiales y métodos. Se hizo un estudio de corte transversal para analizar la formulación de fármacos antirretrovirales en pacientes tratados con estos entre el 1° de abril y el 30 septiembre del 2015. Se determinaron las variables sociodemográficas, farmacológicas y las comorbilidades, y el análisis estadístico se hizo mediante SPSS™, versión 23.0. Resultados. Se hallaron 641 pacientes, la mayoría (60,2 %) hombres, con una edad media de 39,0±17 años. Los medicamentos más empleados fueron lamivudina-zidovudina (51,6 %), lopinavirritonavir (36 %) y efavirenz (24,5 %). La asociación lamivudina-zidovudina más lopinavir-ritonavir fue el esquema más prescrito (29,5 %), pero se encontraron 80 esquemas diferentes. El ser un adulto entre 45 y 64 años (odds ratio=2,25; IC95% 1,367-3,713; p=0,001) se asoció con una mayor probabilidad de recibir cuatro o más antirretrovirales. Del total de pacientes, 267 (41,6 %) recibían más de un medicamento simultáneamente (rango: 1-18 fármacos), especialmente fármacos contra las úlceras (57,3 %), hipolipemiantes (28,8 %) y antihipertensivos (28,5 %). Conclusiones. Los pacientes en tratamiento antirretroviral están recibiendo medicamentos de elevado valor intrínseco en las dosis recomendadas, y presentan las mismas comorbilidades asociadas con las condiciones crónicas relacionadas con la edad. Además, reciben una gran variedad de esquemas que no se encuentran incluidos en las guías de práctica clínica.


Subject(s)
Drug Prescriptions , Antiretroviral Therapy, Highly Active , Acquired Immunodeficiency Syndrome , Pharmacoepidemiology
15.
Rev. enferm. UERJ ; 26: e31156, jan.-dez. 2018. tab
Article in Portuguese | LILACS (Americas), BDENF | ID: biblio-970289

ABSTRACT

Objetivo: descrever o perfil de adesão à terapia antirretroviral (TARV) de pacientes com Síndrome Lipodistrófica do Vírus da Imunodeficiência Humana (SLHIV), em uma unidade especializada do Estado do Pará, Brasil. Método: estudo qualiquantitativo, envolvendo questionário e prontuários de 124 pacientes, no período de fevereiro e março de 2013, após aprovação por Comitê de Ética. Na análise, a variância (p<0,05) articulou testes estatísticos, com dados apresentados em tabelas. Resultados: as dificuldades de entender e conhecer o esquema terapêutico, o Diabetes Mellitus e as alterações da lipodistrofia foram significantes na interferência da adesão à TARV. O grupo de adesão irregular está em risco para a eficácia do tratamento. Os demais têm a possibilidade de migração de um grupo para outro a qualquer momento. Conclusão: o perfil de adesão à TARV não é definida por dados socioeconômicos. A participação em grupos de adesão deve ser estimulada como fator de reversão do padrão de abandono. Descritores: HIV; AIDS; lipodistrofia; adesão à medicação.


Objective: to profile adherence to antiretroviral therapy (ART) by patients with human immunodeficiency virus lipodystrophy syndrome (HIVLS) at a specialized unit in Pará, Brazil. Method: this quali-quantitative study, involving a questionnaire and medical records of 124 patients, was conducted from February to March 2013, after research ethics approval. In the analysis, statistical tests were related by variance (p <0.05) and data were presented in table form. Results: the difficulties of understanding and knowing the therapeutic regimen, mellitus diabetes and changes in lipodystrophy were significant in the interference of ART adherence. The irregular adherence group is at risk for treatment efficacy. The others have the possibility of migrating from one group to another at any time. Conclusion: the profile of adherence to ART is not defined by socioeconomic data. Participation in membership groups should be encouraged as a factor in reversing the pattern of abandonment.


Objetivo: describir el perfil de adhesión a la terapia antirretroviral (TARV) de pacientes con síndrome lipodistrófico del virus de la inmunodeficiencia humana (SLHIV), en una unidad especializada del Estado de Pará, Brasil. Método: estudio cualiquantitativo involucrando cuestionario e historias clínicas de 124 pacientes, en el período de febrero y marzo de 2013, después de la aprobación por el Comité de Ética. En el análisis, la varianza (p <0,05) articuló pruebas estadísticas, con datos presentados en tablas. Resultados: las dificultades en entender y conocer el esquema terapéutico, la Diabetes Mellitus y las alteraciones de la lipodistrofia fueron significantes en la interferencia de la adhesión a la TARV. El grupo de adhesión irregular está en riesgo para la eficacia del tratamiento. Los demás tienen la posibilidad de migración de un grupo a otro en cualquier momento. Conclusión: el perfil de adhesión a la TARV no está definido por datos socioeconómicos. La participación en grupos de adhesión debe ser estimulada como factor de reversión del patrón de abandono.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , HIV Infections/complications , Acquired Immunodeficiency Syndrome/complications , Antiretroviral Therapy, Highly Active , HIV-Associated Lipodystrophy Syndrome , Medication Adherence , Brazil , Epidemiology, Descriptive , Cross-Sectional Studies , Statistics, Nonparametric
16.
Cad. Saúde Pública (Online) ; 34(10): e00009618, oct. 2018. tab, graf
Article in English | LILACS (Americas) | ID: biblio-974575

ABSTRACT

Abstract: The latest Brazilian guideline recommended the reduction of routine CD4+ T cell counts for the monitoring of patients with human immunodeficiency virus type 1 (HIV-1) under combination antiretroviral therapy (cART). The aim of this study was to evaluate the safety of monitoring response to cART in HIV-1 infection using routine viral load at shorter intervals and CD4+ T cell count at longer intervals. CD4+ T cell counts and HIV-1 viral load were evaluated in 1,906 HIV-1-infected patients under cART during a three-year follow-up. Patients were stratified as sustained, non-sustained and non-responders. The proportion of patients who showed a CD4+ T > 350cells/µL at study entry among those with sustained, non-sustained and non-responders to cART and who remained with values above this threshold during follow-up was 94.1%, 81.8% and 71.9%, respectively. HIV-1-infected patients who are sustained virologic responders and have initial CD4+ T cell counts > 350cells/µL showed a higher chance of maintaining the counts of these cells above this threshold during follow-up than those presenting CD4+ T ≤ 350cells/µL (OR = 39.9; 95%CI: 26.5-60.2; p < 0.001). This study showed that HIV-1-infected patients who had sustained virologic response and initial CD4+ T > 350cells/µL were more likely to maintain CD4+ T cell counts above this threshold during the next three-year follow-up. This result underscores that the evaluation of CD4+ T cell counts in longer intervals does not impair the safety of monitoring cART response when routine viral load assessment is performed in HIV-1-infected patients with sustained virologic response.


Resumo: O último consenso brasileiro recomenda reduzir a rotina de contagem de linfócitos T CD4+ para monitorar os pacientes com HIV-1 sob terapia antirretroviral combinada (TARV). O estudo teve como objetivo avaliar a segurança do monitoramento à TARV na infecção pelo HIV-1, realizando a carga viral a intervalos mais curtos e a contagem de linfócitos T CD4+ a intervalos mais longos. Foram avaliadas a contagem de linfócitos T CD4+ e a carga viral do HIV-1 em 1.906 pacientes com HIV-1 em uso de TARV durante um seguimento de três anos. Os pacientes foram estratificados em: resposta sustentada, não sustentada e não respondedores. As proporções de pacientes com linfócitos T CD4+ > 350células/µL na linha de base do estudo entre de resposta sustentada, não sustentada e não respondedores à TARV e que permaneceram com valores acima desse limiar ao longo do seguimento foram 94,1%, 81,8% e 71,9%, respectivamente. Os pacientes com resposta virológica sustentada e que tinham contagem de T CD4+ > 350células/µL mostraram maior probabilidade de manter a contagem acima desse limiar durante o seguimento, quando comparados àqueles com T CD4+ ≤ 350células/µL (OR = 39,9; 95%CI: 26,5-60,2; p < 0,001). O estudo mostrou que pacientes HIV-1+ com resposta virológica sustentada e contagem de linfócitos T CD4+ > 350células/µL tinham maior probabilidade de manter a contagem de células T CD4+ acima desse limiar durante o seguimento de três anos subsequentes. O resultado corrobora que a contagem de linfócitos T CD4+ com intervalos mais longos não compromete a segurança do monitoramento da resposta à TARV quando a avaliação da carga viral é feita de rotina em pacientes HIV-1+ com resposta virológica sustentada.


Resumen: Las últimas directrices brasileñas recomendaron la reducción de la rutina en el recuento celular CD4+ T para pacientes con el virus de inmunodeficiencia humano tipo 1 (VIH-1), con terapia de combinación antirretroviral (cART por sus siglas en inglês). El objetivo de este estudio fue evaluar la seguridad de la monitorización de la respuesta a la cART en una infección por VIH-1, usando rutinas de carga viral en intervalos más cortos y recuento celular CD4+ T en intervalos más largos. Se evaluaron el recuento celular CD4+ T y la carga viral VIH-1 en 1.906 pacientes infectados con VIH-1 y con cART durante un seguimiento que duró tres años. Los pacientes fueron estratificados como constantes, inconstantes y sin respuesta. La proporción de pacientes que mostraron CD4+ T > 350células/µL en el estudio entran dentro del grupo de los constantes, inconstantes y sin respuesta al cART, y quienes permanecieron con valores por encima de este umbral durante los seguimientos fueron 94,1%, 81,8% y 71,9%, respectivamente. Los pacientes infectados por VIH-1 que cuentan con la respuesta virológica constante y tienen un recuento inicial CD4+ T > 350células/µL mostraron una oportunidad más alta de mantener el recuento de estas células por encima del umbral durante los seguimientos, respecto a quienes presentaban CD4+ T células ≤ 350células/µL (OR = 39,9; IC95%: 26,5-60,2; p < 0,001). Este estudio expuso que los pacientes infectados por VIH-1, que habían tenido una respuesta virológica constante e inicial CD4+ T > 350células/µL, eran más propensos a mantener el recuento de células CD4+ T por encima de este umbral durante los tres años posteriores de seguimiento. Este resultado destaca que la evaluación del cómputo de células CD4+ T en intervalos más largos no obstaculiza la seguridad al realizar una monitorización en la respuesta a cART, cuando la evaluación de la carga viral rutinaria se realiza en pacientes infectados por VIH-1 con una respuesta virológica constante.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , HIV Infections/drug therapy , HIV-1/immunology , CD4 Lymphocyte Count/methods , Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active/methods , Socioeconomic Factors , Time Factors , Follow-Up Studies , Longitudinal Studies , HIV-1/drug effects , Anti-HIV Agents/adverse effects , Viral Load/drug effects , Viral Load/immunology , Antiretroviral Therapy, Highly Active/adverse effects , Middle Aged
17.
Int. j. cardiovasc. sci. (Impr.) ; 31(5)set.-out. 2018.
Article in English | LILACS (Americas) | ID: biblio-914814

ABSTRACT

With the advent of the antiretroviral therapy (ART), people infected with HIV are experiencing a significant increase in life expectancy. However, as this population ages, the morbidity and mortality due to events not related to HIV infection and/or treatment become increasingly clear. Cardiovascular diseases are among the major causes of death, and, thus, understanding the factors that trigger this situation is necessary. This review article will assess how the intrinsic and extrinsic factors related to HIV, ART and the associated risk factors can aid the epidemiological transition of mortality in this population. Moreover, we will present the studies on the epidemiology and pathogenesis of each clinical condition related to HIV-infected individuals, in addition to introducing the major markers of cardiovascular disease in this population. Finally, we will point the main issues to be addressed by health professionals for an adequate prognosis


Subject(s)
Humans , Male , Female , Acquired Immunodeficiency Syndrome , Antiretroviral Therapy, Highly Active , Cardiovascular Diseases/complications , Cardiovascular Diseases/mortality , HIV , Acute Retroviral Syndrome , Age Factors , Diabetes Mellitus , Dyslipidemias , Hypertension/complications , Metabolic Syndrome , Myocardial Infarction/complications , Myocardial Infarction/mortality , Risk Factors , Sex Factors , Illicit Drugs/adverse effects , Tobacco Use Disorder/complications , Zidovudine/therapeutic use
18.
An. bras. dermatol ; 93(4): 524-528, July-Aug. 2018. tab, graf
Article in English | LILACS (Americas) | ID: biblio-949915

ABSTRACT

Abstract: Background: Kaposi's sarcoma (KS) is a rare neoplasm with indolent progression. Since 1981, the Kaposi's sarcoma epidemic has increased as co-infection with HIV. Objectives: The study aimed to identify the clinical and demographic characteristics and therapeutic approaches in HIV/AIDS patients in a regional referral hospital. Methods: We analyzed the medical records of 51 patients with histopathological diagnosis of Kaposi's sarcoma hospitalized at Hospital Universitário João de Barros Barreto (HUJBB) from 2004 to 2015. Results: The study sample consisted of individuals 15 to 44 years of age (80.4%), male (80.4%), single (86.3%), and residing in Greater Metropolitan Belém, Pará State, Brazil. The primary skin lesions identified at diagnosis were violaceous macules (45%) and violaceous papules (25%). Visceral involvement was seen in 62.7%, mainly affecting the stomach (75%). The most frequent treatment regimen was 2 NRTI + NNRTI, and 60.8% were referred to chemotherapy. Study limitations: We assumed that more patients had been admitted to hospital without histopathological confirmation or with pathology reports from other services, so that the current study probably underestimated the number of KS cases. Conclusion: Although the cutaneous manifestations in most of these patients were non-exuberant skin lesions like macules and papules, many already showed visceral involvement. Meticulous screening of these patients is thus mandatory, even if the skin lesions are subtle and localized.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Young Adult , Sarcoma, Kaposi/epidemiology , AIDS-Related Opportunistic Infections/epidemiology , Sarcoma, Kaposi/pathology , Sarcoma, Kaposi/drug therapy , Socioeconomic Factors , Brazil/epidemiology , Cross-Sectional Studies , Retrospective Studies , AIDS-Related Opportunistic Infections/pathology , AIDS-Related Opportunistic Infections/drug therapy , Antiretroviral Therapy, Highly Active , Tertiary Care Centers
20.
Saude e pesqui. (Impr.) ; 11(2): 307-314, Maio-Ago 2018. tab
Article in Portuguese | LILACS (Americas) | ID: biblio-912514

ABSTRACT

Avaliar a adesão ao tratamento antirretroviral de pessoas que vivem com HIV através do "Cuestionario para la Evaluación de la Adhesión al Tratamiento Antiretroviral" (CEAT-VIH), de forma a descrever seus itens a partir da correlação entres as questões deste instrumento. Estudo transversal, realizado em um Hospital Universitário do Rio Grande do Sul no primeiro semestre de 2012 com 179 pessoas em tratamento para o HIV. Foram realizadas análises estatísticas descritivas e de correlação entre os itens do questionário. Avaliação da adesão: 46,4% baixa/insuficiente, 36,9% boa/adequada e 16,8% estrita. Correlações: deixar de tomar a medicação relaciona-se aos fatos de se sentir melhor/pior, ou sentir-se triste/deprimido. Seguir a prescrição médica está relacionado com a autoavaliação em relação à ingesta dos medicamentos. A baixa/inadequada adesão legitima o uso do CEAT-VIH enquanto ferramenta a ser utilizada pela enfermagem junto à equipe multiprofissional no planejamento do cuidado e intervenção nas situações que interferem na adesão.


Current analysis assesses adhesion to anti-retroviral treatment in HIV patients by "Cuestionario para la Evaluación de la Adhesión al Tratamiento Antiretroviral" (CEAT-VIH), for the description of items by co-relation between the instrument´s issues. The transversal study was performed at the Hospital Universitário do Rio Grande do Sul during the first semester of 2012, comprising 179 people undergoing HIV treatment. Descriptive statistical and co-relation analyses between the questionnaire´s items were performed. Adhesion evaluation was as follows: 46.4% low/insufficient; 36.9% good/adequate; 16.8% strict. Co-relationship: not taking medicine is related to feeling better/worse, or feeling bad, depressed. Following the doctor´s prescription is related to self-evaluation with regard to taking medicines. Low/inadequate adhesion triggers the use of CEAT-VIH as a tool that may be used by nurses plus a multiprofissional team in the planning of care and intervention in situations that impair adhesion.


Subject(s)
Humans , Sexually Transmitted Diseases , Acquired Immunodeficiency Syndrome , HIV , Nursing , Antiretroviral Therapy, Highly Active , Medication Adherence
SELECTION OF CITATIONS
SEARCH DETAIL